Arrhythmias & electrophysiology
Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial
Corrected 23 Oct 2026: Measure wording clarified; no values changed.
Authors' conclusion
Treatment with SSYX following radiofrequency catheter ablation for persistent AF reduced the incidence of recurrent atrial tachyarrhythmias and led to clinically significant improvements in QoL during a 12-month follow-up in a Chinese population.
Study context
- Population
- Patients with persistent atrial fibrillation (AF) undergoing first catheter ablation
- Participants
- 920 patients
- Comparison
- SSYX vs placebo
- SSYXn = 460
- Placebon = 460reference
- Primary endpoint
- Recurrent atrial tachyarrhythmias lasting ≥30 s after a 3-month blanking period
- Follow-up
- 12 months
Methodological detailsmulticentre, double-blind, placebo-controlled, 66 centres in China
- Multicentre
- Double-blind
- Placebo-controlled
- 66 centres in China
Primary result
As reported in the abstract
12-month Kaplan-Meier event-free rate from recurrent atrial tachyarrhythmias
HR for recurrent atrial tachyarrhythmias
.6
95% CI .4-.8
P = 0.001
By group
SSYXvs Placebo
HR for recurrent atrial tachyarrhythmias .6 (95% CI .4-.8); P = 0.001
Secondary outcomes
Quality-of-life (QoL) score · 12 months
- Better QoL score with SSYX vs placebo
Safety
Serious adverse events
- No significant difference between the two groups
Original publication
Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial. Eur Heart J. Published 23 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →